Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results
SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss today's announcement of the interim results of its phase II/III RAPID trial comparing CHOP-R to CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R, in first-line treatment of patients with aggressive non-Hodgkin's lymphoma.
Conference Call Numbers
Wednesday, July 11
1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European
1-800-240-7305 (US Participants)
1-303-262-2137 (International)
Live audio webcast at
www.cticseattle.com
will be archived for post listening
approximately two hours after call ends, available for five days
Call-back numbers for post listening available at 6:30 p.m. Eastern:
1-800-405-2236 (US Participants)
1-303-590-3000 (International)
Passcode: 11093505#
Media Contact:
Cell Therapeutics, Inc.
Dan Eramian
T: 206.272.4343
C: 206.854.1200
Susan Callahan
T: 206.272.4472
F: 206.272.4434
E:
www.cticseattle.com/media.htm
Investors Contact:
Cell Therapeutics, Inc.
Leah Grant
T: 206.282.7100
F: 206.272.4434
E:
www.cticseattle.com/investors.htm
media@ctiseattle.com invest@ctiseattle.com
CONTACT: media, Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, orSusan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or, or investors, Leah Grant, +1-206-282-7100, or fax,+1-206-272-4434, or , all for Cell Therapeutics, Inc. media@ctiseattle.com invest@ctiseattle.com
Web site: http://www.cticseattle.com//
Ticker Symbol: (NASDAQ-NMS:CTIC)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: July 2007
